Does information from ClinicalTrials.gov increase transparency and reduce bias? Results from a five-report case series
Abstract Background We investigated whether information in ClinicalTrials.gov would impact the conclusions of five ongoing systematic reviews. Method We considered five reviews that included 495 studies total. Each review team conducted a search of ClinicalTrials.gov up to the date of the review’s l...
Main Authors: | Gaelen P. Adam, Stacey Springs, Thomas Trikalinos, John W. Williams, Jennifer L. Eaton, Megan Von Isenburg, Jennifer M. Gierisch, Lisa M. Wilson, Karen A. Robinson, Meera Viswanathan, Jennifer Cook Middleton, Valerie L. Forman-Hoffman, Elise Berliner, Robert M. Kaplan |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2018-04-01
|
Series: | Systematic Reviews |
Online Access: | http://link.springer.com/article/10.1186/s13643-018-0726-5 |
Similar Items
-
Registration of phase 3 crossover trials on ClinicalTrials.gov
by: Lijuan Zeng, et al.
Published: (2020-07-01) -
2557 Improving ClinicalTrials.gov compliance: A coordinated effort for success
by: Scott Patton, et al.
Published: (2018-06-01) -
Problematic trial detection in ClinicalTrials.gov
by: Chris Hartgerink, et al.
Published: (2015-12-01) -
Some data quality issues at ClinicalTrials.gov
by: Neha Chaturvedi, et al.
Published: (2019-06-01) -
Amphetamines in child medicine: a review of ClinicalTrials.gov
by: Samer O. Alalalmeh, et al.
Published: (2023-10-01)